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Background: The polymorphisms in the components of the renin-angiotensin system (RAS) are important in the
development and progression of coronary artery disease (CAD) in some individuals. Our objectives in the present
investigation were to determine whether three RAS polymorphisms, angiotensin-converting enzyme insertion/
deletion (ACE I/D), angiotensin receptor II (Ang II AT2 - C3123A) and angiotensinogen (AGT-M235T), are associated
with CAD in the Saudi population. We recruited 225 subjects with angiographically confirmed CAD who had
identical ethnic backgrounds and 110 control subjects. The polymerase chain reaction-restriction fragment length
polymorphisms (RFLP) technique was used to detect polymorphisms in the RAS gene.
Results: Within the CAD group, for the ACE I/D genotype, DD was found in 64.4%, 26.3% carried the ID genotype,
and 9.3% carried the II genotype. Within the control group, the DD genotype was found in 56.4%, 23.6% carried the
ID genotype, and 20% carried the II genotype. The odds ratio (OR) of the ACE DD vs II genotype with a 95%
confidence interval (CI) was 2.45 (1.26-4.78), with p = 0.008. For the Ang II AT2 receptor C3123A genotype, within
the CAD group, CC was found in 39.6%, 17.8% carried the CA genotype, and 42.6% carried the AA genotype. Within
the control group, CC was found in 39.1%, 60.9% carried the CA genotype, and there was an absence of the AA
genotype. The OR of the Ang II AT2 receptor C3123A CC vs AA genotypes (95% CI) was 0.01, with p = 0.0001. A
significant association with CAD was shown. For the AGT-M235T genotype, within the CAD group, MM was found
in 24.0%, 43.6% carried the MT genotype and 32.4% carried the TT genotype. Within the control group, MM was
found in 26.4%, 45.5% carried the TT genotype and 28.2% carried the MT genotype. The OR of MM vs TT (95% CI)
was 0.79 (0.43 to 1.46), which was insignificant.
Conclusions: There is an association between the ACE I/D and Ang II AT2 receptor C3123A polymorphisms and
CAD, however, no association was detected between the AGT M235T polymorphism and CAD in the Saudi
population.
Keywords: Coronary artery disease, Angiotensin, Genotypes, Angiotensin converting enzyme, Angiotensin receptors,
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The renin-angiotensin system, which regulates blood
pressure, plays a pivotal role in the pathogenesis of CAD
[1]. Several studies have suggested that polymorphisms
in the components of the renin-angiotensin system
(RAS) are important in the development and progres-
sion of CAD in some individuals. This has been sup-
ported by the evidence of the efficacy of angiotensin-
converting enzyme (ACE) inhibitors and angiotensin-II* Correspondence: ajafari@ksu.edu.sa
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article, unless otherwise stated.receptor blockers (ARBs) in halting the development of
coronary atherosclerosis and related coronary events [2].
ACE, a key component of the RAS, is a peptidase that
cleaves the histidyl-leucine dipeptide from inactive angio-
tensin I. It is well documented that angiotensin-converting
enzyme (ACE, EC 3.4.15.1) gene polymorphisms are
associated with various diseases such as hypertension,
coronary artery disease, myocardial infarction and dia-
betes [3].
Angiotensin I (Ang I) generates vasoactive angiotensin
II, which is a potent vasopressor. Angiotensin II affects
the contractility and growth of the vascular endothelium
and vascular smooth muscle cells (VSMC) and plays atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Demographic characteristics of the control
subjects and the CAD patients
Characteristic Controls CAD group p level
n = 110 n = 225
Age, years
Mean ± SD 46.61 ± 16.15 61.22 ± 10.35 < 0.0001
Range (20.0-78.0) (31.0-89.0)
Gender
Male (%) 62 (56.4%) 153 (68.0%) < 0.0001
Female (%) 48 (43.6%) 72 (32.0%)
FBS, mmol l−1
Mean ± SD 4.48 ± 0.64 8.08 ± 3.41 < 0.0001
Range (3.20-7.10) (3.3-20.6)
TG, mmol l−1
Mean ± SD 1.11 ± 0.27 1.87 ± 1.19 < 0.0001
Range (0.50-1.90) (0.60-8.70)
TC, mmol l−1
Mean ± SD 3.81 ± 0.54 4.16 ± 0.99 < 0.001
Range (3.00-7.10) (0.80-7.5)
HDL-c, mmol l−1
Mean ± SD 1.24 ± 0.36 1.15 ± 0.95 0.340
Range (0.80-2.20) (0.50-10.7)
LDL-c, mmol l−1
Mean ± SD 1.65 ± 0.59 2.37 ± 0.85 < 0.0001
Range (0.90-4.50) (0.60-5.90)
The Student’s t-test and the χ2 test were used to compare the values of the
controls and the CAD patients.
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opment of the hyperplastic and hypertrophic VSMC pro-
liferation and migration; this results in stimulation of the
synthesis of plasminogen activator inhibitor-1 by fibro-
blasts, which results in chronic and acute coronary
disorders [4]. Several studies have suggested that the
major components of the RAS, ACE and Ang II, pos-
sess considerable effects in cardiovascular disease pro-
cesses and might be modulated by some components of
gene abnormalities and disorders. This is supported in
part by the results of association studies that focused
on the involvement of polymorphisms in the genes of
the RAS pathway components and cardiac disease dis-
orders [5].
Various studies have reported a relationship between
ACE gene I/D polymorphisms and cardiovascular disor-
ders. A report by Cambien et al. in 1992 first predicted
the strong relationship of the ACE D allele as an inde-
pendent risk factor for myocardial infarction (MI) [3],
and studies were later conducted intensively to investi-
gate the relationship between ACE gene I/D polymor-
phisms and CAD in different individuals from different
populations, yet their results were inconsistent [6,7].
These variations are likely due to various environmental
and genetic factors that have not been explored or inves-
tigated separately. However, the relationship between
polymorphisms in Ang II, AT1, and AT2 receptors and
CAD has been reported by several investigators [8,9]. An
angiotensinogen (AGT) gene polymorphism (M235T)
has been proposed to be associated with CAD [10,11].
Given this background, the aim of the present study was
to assess the possible association between, angiotensin-
converting enzyme insertion/deletion (ACE I/D), angioten-
sin receptor II (Ang II AT2-C3123A) and angiotensinogen
(AGT-M235T) in Saudi patients with coronary artery
disease as confirmed by coronary angiography diagnosis,
because the contribution of these RAS polymorphisms to
the pathogenesis of CAD has not been studied previously
in Saudi CAD patients.Results
Demographic characteristics of the control subjects and
the CAD patients
Two hundred twenty-five CAD patients and one hun-
dred and ten control subjects were studied. Table 1
shows their clinical characteristics. There was a signifi-
cant difference between the CAD patients and the con-
trol subjects with regard to age, gender, plasma fasting
blood sugar (FBS), triglycerides (TG), low-density
lipoprotein-cholesterol (LDL-c) (p < 0.0001) and TC (p <
0.001). There was no difference between the CAD patients
and the control subjects in the high-density lipoprotein-
cholesterol (HDL-c) (p =0.34).CAD risk factors in the patients and the control subjects
Other demographic characteristics are listed in Table 2.
There were significant differences between the CAD pa-
tients and the control group with regard to diabetes melli-
tus, dyslipidemia, hypertension, and smoking. Using the χ2
test, diabetes mellitus (p < 0.0001, OR = 20.34, 95% CI:
9.78-4.24), dyslipidemia (p < 0.0001, OR = 9.38, 95% CI:
5.05-17.44), hypertension (p < 0.0001, OR = 22.46, 95%
CI: 11.51-43.81), and smoking (p < 0.0001, OR = 3.85, 95%
CI: 2.12-6.96) were found to be independent risk factors
of CAD.
ACE I/D, Ang II AT2 receptor C3123A and AGT M235T
genotype distributions and allele frequencies in Saudi
CAD and healthy patients
Genotype frequencies did not deviate from Hardy-Weinberg
expectations in both controls and CAD group. The genotype
frequencies are listed in Table 3. A significant difference
in the genotype distribution of ACE I/D and Ang II AT2
receptor C3123A polymorphisms were observed between
the CAD patients the and control subjects (p = 0.023 and
Table 2 CAD risk factors in the patients and the control
subjects
Parameter CAD Control OR 95% CI p level
(n = 225) (n = 110)
Diabetes mellitus
Diabetic 145 (64.4%) 9 (8.2%)
Non-diabetic 80 (35.6%) 101(91.8%) 20.34 9.78-42.40 < 0.0001
Dyslipidemia
Positive 130 (57.8%) 14 (12.7%)
Negative 95 (42.2%) 96 (87.3%) 9.38 5.05-17.44 < 0.0001
Hypertension
Hypertensive 165 (73.3%) 12 (10.9%)
Normotensive 60 (26.7%) 98 (89.1%) 22.46 11.51-43.81 < 0.0001
Smoking
Smoker 89 (39.6%) 16 (14.5%)
Non-smoker 136 (60.4%) 94 (85.5%) 3.85 2.12-6.96 < 0.0001
Table 4 ACE I/D, Ang II AT2 receptor C3123A, and AGT
M235T allele frequencies in CAD and healthy patients
Alleles Groups
Total p valueControl CAD patients
(n = 110) (n = 225)
ACEI/D
D 150 (68.18%) 349 (77.56%) 499 (74.48%)
0.009
I 70 (31.82%) 101 (22.44%) 171 (25.52%)
Total 220 450 670
Ang II AT2 (C3123A)
C 153 (69.54%) 218 (48.44%) 371 (55.37%)
0.0001
A 67 (30.46%) 232 (51.56%) 299 (44.63%)
Total 220 450 670
AGT (M235T)
M 108 (49.09%) 206 (45.78%) 314 (46.87%)
0.419
T 112 (50.91%) 244 (54.22%) 356 (53.13%)
Total 220 450 670
The χ2 test was used to compare the allele frequencies between the control
and CAD patients.
Al-Hazzani et al. Journal of Biological Research-Thessaloniki 2014, 21:8 Page 3 of 9
http://www.jbiolres.com/content/21/1/80.0001, respectively), however no significant differences
were observed in the genotype distribution of AGT
M235T between the CAD patients and the control sub-
jects (p = 0.102). Table 4 shows the significant differences
in D and I and in C and A allele distributions observed
between the CAD and the control groups (p = 0.009 and
0.0001, respectively). No significant differences in M and
T allele distributions were observed between the CAD
and the control groups (p = 0.419).Table 3 ACE I/D, Ang II AT2 receptor C3123A, and AGT
M235T genotype distributions in CAD and healthy
patients
Genotype Groups p value
Control CAD patients Total
(n = 110) (n = 225) (n = 335)
ACE I/D
DD 62 (56.4%) 145 (64.4%) 207 (61.79%)
0.023ID 26 (23.6%) 59 (26.3%) 85 (25.37%)
II 22 (20.0%) 21 (9.3%) 43(12.84%)
Ang II AT2 (C3123A)
CC 43 (39.1%) 89 (39.6%) 132 (39.40%)
0.0001CA 67 (60.9%) 40 (17.8%) 107 (31.94%)
AA 0 96 (42.6%) 96 (28.66%)
AGT (M235T)
MM 29 (26.40%) 54 (24.0%) 83 (24.78%)
0.102MT 50 (45.50%) 98 (43.6%) 148 (44.18%)
TT 31 (28.20%) 73 (32.4%) 104 (31.04%)
The χ2 test was used to compare the genotype distributions between the
control and CAD patients.CAD odds ratio associations with ACE I/D, Ang II AT2
receptor C3123A and AGT M235T genotypes
The odds ratios of the ACE I/D genotype DD vs II, DD +
ID vs II and ID vs II genotypes (95% CI) were 2.45 (1.26-
4.78), 2.43 (1.27-4.64), and 2.38 (1.12-5.06). These results
demonstrate a significant association with CAD disease
(p = 0.008, 0.007 and 0.02, respectively). The odds ratios
of the Ang II AT2 receptor C3123A genotype CC vs CA
and CC + AA vs CA (95% CI) were 3.45 (2.03-5.92) and
7.21 (4.31-12.04), respectively, which shows a significant
association with CAD disease (p < 0.0001). The odds ratio
of the ACT M235T genotype MM vs MT, MM vs TT,
MM vs MT + TT, and MM + TT vs MT (95% CI) were
0.95 (0.54-1.67), 0.79 (0.43-1.46), 0.88 (0.52-1.49), and 1.08
(0.68-1.71), respectively, indicating that there was no sig-
nificant association with CAD disease (Table 5).
Frequencies of the ACE I/D, Ang II AT2 receptor C3123A,
and ACT M235T genotype combinations in the CAD and
control groups
Our study revealed 26 ACE I/D, Ang II AT2 receptor
(C3123A), and ACT (M235T) genotype combinations. The
DDAAMT (OR = 30.62, 95% CI = 1.85-506.8, p = 0.016),
DDAAMM (OR = 23.23, 95% CI = 1.39-387.2, p = 0.028),
DDAATT (OR = 19.70, 95% CI = 1.18-330.1, p = 0.038),
IDAAMT, IDCCTT, IDAATT, IDAAMT, IIAAMT, and
IIAATT genotype combinations were observed only in
the CAD group. The DDACTT, IDACMT, IDACMM,
DDACMM, IICCTT, and IIACTT genotype combina-
tions were significantly more common in the control
group compared with the CAD group (p = 0.018, 0.016,
0.038, 0.005, 0.019 and 0.023, respectively) (Table 6).
Table 5 CAD odds ratio associations with ACE I/D, Ang II
AT2 receptor C3123A, and AGT M235T genotypes
OR 95% CI p value
ACE I/D genotypes
ID vs II 2.38 (1.12-5.06) 0.02
DD vs II 2.45 (1.26-4.78) 0.008
DD vs ID 1.03 (0.60-1.78) 0.914
DD vs ID and II 1.40 (0.88-2.23) 0.15
DD and ID vs II 2.43 (1.27-4.64) 0.007
Ang II AT2 (C3123A) genotypes
CC vs CA 3.45 (2.03-5.92) < 0.0001
CC vs AA 0.01 (0.001-0.18) 0.001
CC vs CA and AA 1.02 (0.64-1.63) 0.93
CC and AA vs CA 7.21 (4.31-12.04) < 0.0001
AGT (M235T) genotypes
MM vs MT 0.95 (0.54-1.67) 0.86
MM vs TT 0.79 (0.43-1.46) 0.46
TT vs MT 1.20 (0.70-2.06) 0.51
MM vs MT and TT 0.88 (0.52-1.49) 0.64
MM and TT vs MT 1.08 (0.68-1.71) 0.74
CI = confidence interval.
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The renin-angiotensin system (RAS) has a prominent
role in the physiological functions of cardiovascular sys-
tem and in the pathophysiology of heart diseases such
as CAD [12]. CAD is a polygenic disease, the onset and
severity of CAD depends on the interaction of many
genetic and environmental factors [13]. The association
of these RAS gene polymorphisms with classical risk
factors including hypertension, obesity, diabetes, and
hyperlipidemia has been reported [14-18]. In this study,
diabetes mellitus, dyslipidemia, hypertension, and smok-
ing were found to be risk factors for CAD (odds 20.34,
9.38, 22.46 and 3.85, respectively, p < 0.0001). Previous
studies had indicated an association of the DD genotype
with CAD in high-risk patients diagnosed with diabetes
mellitus [19]. The DD genotype (vs the II genotype) inde-
pendently increased the risk of CAD in diabetes 2.1-fold,
while the ID genotype did not alter the risk significantly
[20]. Hyperlipidemia as a major risk factor of CAD in-
creases the plasma concentration of angiotensinogen and
the angiotensin peptides II and III and up-regulates the
expression of the angiotensin II type 1 receptor (AT1R)
gene [16]. Although the positive relationship between the
DD genotype, the D allele frequency and hyperlipidemia
was demonstrated by prior studies [17,21], Oren et al.
reported higher LDL cholesterol levels in patients with
the DD genotype, intermediate levels in the ID patients,
and lower levels in the II patients [18]. Other studies
did not find any correlation between the lipid profileand polymorphisms [17,19,22,23]. The ACE I/D poly-
morphism has been extensively studied and points to an
association with arterial hypertension [24]. Cigarette
smoking is another risk factor for CAD, and is particu-
larly common in Turkish patients [14]. Previous data
have suggested that nicotine increases ACE expression
[25] and the D allele smokers have been found to be as-
sociated with endothelial dysfunction [26]. Moreover,
smoking patients with ID genotype were found to have
an increased risk of CAD and an association between
the ID genotype, hyperlipidemia and cigarette smoking
has been proposed [13].
Genetic factors play a role in the development of
CAD but differ among various populations. The ACE I/
D gene polymorphisms are the most frequently studied
and have been proposed as CAD risk factors [27]. In the
present study, samples from CAD patients and controls
were investigated to assess the relationship between
three RAS polymorphisms with CAD in a sample of
Saudi patients. We found that the ACE D and I alleles
differ significantly between CAD group and controls
(p = 0.009) and a significant association between the DD
genotype polymorphisms and CAD (p = 0.008, OR: 2.45,
95% CI = 1.26-4.78) was observed. Our results are con-
sistent with previous studies (although the relationship
between CAD and ACE gene polymorphism (DD geno-
type) was first reported by Cambien et al. [3]). Beohar et al.
considered that the ACE D allele and DD genotype were
the major risk factors for CAD [28]. Since then, many
studies have found the D allele or DD genotype to be as-
sociated with myocardial infarction, coronary heart dis-
ease [8] or other cardiovascular pathology, hypertrophic
cardiomyopathy [29], and coronary artery stenosis [30].
The DD polymorphism was more closely associated
with CAD than the other two genotypes (ID and II) in
CAD patients [31]. On the other hand, several studies
found no association with the occurrence of either CAD
or MI [32]. There were relationships between the pres-
ence of CAD and the ACE D allele in a large case-
controlled study [33]. Ethnic differences can explain the
disparity between prior clinical studies. In 2005, Acartürk
et al. showed that the DD genotype is a significant pre-
dictor of CAD in a population living in Southern Turkey
[14]. The DD genotype of the ACE I/D gene has been
reported as a risk factor for the development of various
heart diseases in Caucasian, Chinese, and Australian
populations [34,35]. The DD genotype frequency of the
ACE I/D polymorphism was markedly higher in CAD
depressed Iranian patients than in the non-CAD de-
pressed control group, and it was associated with a
2.32-fold increased risk of CAD. The DD genotype of
ACE I/D (vs the II genotype) could independently and
strongly increase the risk of CAD by 9.4-fold in depressed
CAD individuals [11]. The ACE I/D polymorphism did
Table 6 Genotype combination frequencies of the ACE I/D, Ang II AT2 receptor C3123A, and AGT M235T
Genotype combination CAD (n = 225) Controls (n = 110) OR 95% CI p
n (%) n (%)
DDAAMT 27 (12.0%) 0 30.62 1.85-506.8 0.016
DDCCTT 23 (10.22%) 15 (13.64%) 0.72 0.36-1.44 0.356
DDAAMM 21 (9.33%) 0 23.23 1.39-387.2 0.028
DDCCMT 20 (8.89%) 7 (6.36%) 1.44 0.59-3.50 0.427
DDAATT 18 (8.0%) 0 19.70 1.18-330.1 0.038
DDACMT 13 (5.78%) 13 (11.82%) 0.46 0.204-1.02 0.057
DDCCMM 11 (4.89%) 6 (5.45%) 0.89 0.32-2.48 0.825
IDCCMT 11 (4.89%) 1 (0.91%) 5.60 0.71-43.96 0.101
IDAAMT 10 (4.44%) 0 10.77 0.63-185.5 0.101
DDACTT 9 (4.0%) 12 (10.91%) 0.34 0.14-0.83 0.018
IDCCTT 7 (3.11%) 0 7.59 0.43-134.0 0.167
IDAATT 7 (3.11%) 0 7.59 0.43-134.0 0.167
IICCMT 6 (2.67%) 3 (2.73%) 0.98 0.24-3.98 0.974
IDAAMT 6 (2.67%) 0 6.54 0.37-117.2 0.201
IDACTT 5 (2.22%) 7 (6.36%) 0.33 0.10-1.08 0.067
IICCMM 5 (2.22%) 3 (2.73%) 0.81 0.19-3.46 0.776
IDCCMM 5 (2.22%) 2 (1.82%) 1.23 0.23-6.43 0.808
IDACMT 5 (2.22%) 9 (8.18%) 0.26 0.08-0.78 0.016
IIAAMT 4 (1.78%) 0 4.49 0.24-84.14 0.315
IDACMM 4 (1.78%) 7 (6.36%) 0.27 0.08-0.93 0.038
DDACMM 3 (1.33%) 9 (8.18%) 0.15 0.04-0.57 0.005
IIAATT 3 (1.33%) 0 3.51 0.18-68.52 0.408
IIACMT 1 (0.44%) 2 (1.82%) 0.24 0.02-2.68 0.248
IICCTT 1 (0.44%) 6 (5.45%) 0.08 0.01-0.65 0.019
IIACMM 0 2 (1.82%) 0.10 0.001-2.02 0.132
IIACTT 0 6 (5.45%) 0.04 0.002-0.64 0.023
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Western, Australian and Caucasian population [27,28].
Some studies indicated the lack of an association between
the DD genotype and CAD in low risk populations [36].
AT2 receptor is believed to be increased under some
pathological conditions such as hypertension, vascular
injury, and stroke [19]. In the present study, CAD was
associated with AT2 receptor C3123A genetic poly-
morphism in accordance with a previous study between
an Ang II AT2 receptor polymorphism (C3123A) and
CAD [37]. However, other authors have failed to show
any associations [38]. Firouzabadi et al. showed higher
frequency of the AA genotype (C3123A) of AT2 recep-
tors, but no association was observed between these ge-
notypes and CAD among CAD depressed patients [11].
This might be due to the low expression of these vari-
ants in most populations studied, and these polymor-
phisms may become associated with CAD in studies
with larger sample sizes [11]. Japanese men carried (A)allele of the C3123A polymorphism which was observed
to be associated with an increase in blood pressure
whereas carriers of the (C) allele did not show this asso-
ciation [39].
The distribution of the angiotensinogen (AGT) geno-
type is an ethnic difference. Asians and Blacks have higher
frequencies of T235 homozygosity than the Caucasian
population [40]. The AGT gene polymorphisms (M235T)
have been proposed to be associated with CAD [10] and a
meta-analysis that included twelve studies demonstrated
no association in this regard [41]. Angiotensinogen-235 T
was present in 19% of the control population compared
with 15% of the individuals in Western populations, and
an association was seen between the AGT gene and the
risk for coronary heart disease (CHD) [42]. The presence
of the AGT M235 homozygote was associated with a 2-
fold increase of myocardial infarction risk. In the Spanish
and New Zealand populations, T235 homozygosity was
associated with an increased risk of CAD [43,44]. In the
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(MM, MT and TT) frequencies in Saudi CAD patients
were 24, 43.6 and 32.4%, respectively and there was no
significant difference between the M and T alleles and no
significant association with CAD disease was observed.
Kuo et al. found that the AGT M235T polymorphism was
not related to the presence of CAD. In the same study the
AGT genotypes were MM in 3.7%, MT in 49.5%, and TT
in 46.7% in the control group, which are comparable to
our investigation [45]. However, the presence of T235
homozygosity of the AGT gene was not associated with
the existence of CAD but was associated with an in-
creased risk of CHD and essential hypertension in a
Japanese population [39,45]. In contrast, it was associated
with CAD in white Europeans [44].
The combined set of RAS alleles ACE I/D D/AGT235
T/AT1R A was the only parameter which was found to
be significantly increased as a risk factor of CAD in the
whole population analysis studied before [15]. The inter-
action between AGT TT and ACE ID genotypes has
been previously observed among no diabetic patients
with clinically diagnosed CAD [41]. Sekuri et al. demon-
strated that an increased premature CHD risk is associ-
ated with higher frequencies of the ACE DD and AGT
MM genotypes [46]. In our study, the genotype combi-
nations, DDAAMT, DDAAMM and DDAATT were ob-
served only in the CAD group compared to the wild
type. Also it is well documented that the RAS genetic
polymorphisms (ACE DD, AGT TT, and ATR1 CC) may
increase the susceptibility of an individual to have pre-
mature CAD [38].
Conclusions
We found an association between the ACEI/D and Ang
II AT2 receptor C3123A polymorphisms and CAD, but
we did not find an association between the AGT M235T
polymorphism and CAD. A combination of genetic and
environmental factors may influence the onset of CAD,
and RAS gene polymorphisms have a strong role in the
development of CAD. Further studies with a larger study
population on other RAS gene polymorphisms are ne-




Two hundred twenty-five CAD patients (156 males and
69 females, aged 42–82 years old) who were admitted to
Department of Cardiology, King Khalid University Hos-
pital, Riyadh, Saudi Arabia and a control group of 110
healthy subjects (59 males and 51 females, aged 20–78
years old) who had no history of CAD were included in
this study. The included subjects were of unrestricted
age and gender and provided written informed consentfor drawing blood at the time of angiography or at the
time of screening for research deoxyribonucleic acid
(DNA) extraction to be used in studies approved by the
hospital’s institutional review board. The study was con-
ducted in accordance with the guidelines set by the eth-
ics committee of College of Medicine and Research
Centre (CMRC) of King Saud University, Riyadh, Saudi
Arabia. All the subjects enrolled in this study were Saudi
residents with similar dietary patterns. The key demo-
graphic data of the subjects were recorded including the
age, gender, and lipid profile. Assessments of CAD were
made by the patients’ cardiologists through the reviewing
of angiograms.
Ethical approval
This study was conducted after review and approval of the
Institutional Review Board of the Ethics Committee at
KKUH (King Khalid University Hospital), and all subjects
gave written informed consent prior to participation.
Sample collection and lipid analysis
The blood samples for glucose and lipid measurements
were drawn from the patients and the control subjects
after an overnight fast. The plasma glucose concentra-
tion was measured by the glucose oxidase method using
a Biotrol Kit (BIOTROL, USA) on a Bayer opera analyzer
(Bayer Diagnostics - Siemens, Germany). The serum total
cholesterol was measured using the Biotrol commercial
Kit. The HDL cholesterol was determined with a com-
mercial Randox Kit (Randox Laboratories Ltd., United
Kingdom). The LDL cholesterol was calculated by the
formula of Friedwald. The triglyceride determination
was made by the method of Lipase/Glycerol Kinase UV
endpoint on the opera analyzer.
DNA extraction
Genomic DNA was extracted from the peripheral blood
(in tubes containing EDTA as an anticoagulant) using the
QIAamp DNA isolation Kit from QIAGEN (Germany).
Genotyping and polymorphism analysis
Genotyping of ACE I/D, C3123A, and M235T polymor-
phisms were determined using polymerase chain reaction
restriction fragment length polymorphism (PCR-RFLP)
from genomic DNA. The primer sets were selected on
the basis of previously published information [2,3,47]:
ACE I/D, forward primer: 5′-CTG GAG ACC ACT
CCC ATC CTT TCT-3′ and reverse primer: 5′-GAT
GTG GCC ATC ACA TTC GTC AGT T-3′; Ang II AT2
receptor (C3123A), forward primer: 5′-GGA TTC AGA
TTT CTC TTT GAA-3′ and reverse primer: 5′-GCA
TAG GAG TAT GAT TTA ATC-3′; AGT (M235T), for-
ward primer: 5′-CAG GGT GCT GTC CAC ACT GGA
CCC C-3′ and reverse primer: 5′-CCG TTT GTG CAG
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3 μL (150 ng) was added to the PCR reaction mixture
containing 12.5 μL of 2× Promega master mixes, 2 μL of
each primer and distilled water to a final volume of
25 μL. The PCR conditions were: initial denaturation at
94°C for 2 min followed by 40 cycles of denaturation at
94°C for 15 s, annealing at 50°C for 30 s, and extension
at 72°C for 1 min, and a final extension at 72°C for 2 min
in a My Cycler (Bio-Rad). Digestion of the C3123A and
M235T PCR products was performed by the addition of
1 μL of the appropriate restriction enzyme (AluI and
PflFI: New England Biolabs Inc., UK) to 10 μL of PCR
products in 2 μL of a 10× buffer solution (final reaction
volume = 20 μL). The mixture was centrifuged for 2 min
at 5000 rpm and kept in a water bath at 37°C overnight.
The resulting fragments were resolved by electrophor-
esis (80 V, 60 min) on 3.0% agarose gels and directly vi-
sualized under UV light. For ACE I/D the homozygous
individuals for the D allele (DD genotype) were identi-
fied by the presence of a single 190 bp PCR product.
The homozygous for I allele (II genotype) were identi-
fied by the presence of a single 490 bp PCR product.
The heterozygous individuals (ID genotype) were identi-
fied by the presence of both 190 bp and 490 bp PCR
products. For Ang II AT2 receptor (C3123A) the homo-
zygous individuals for the C allele (CC genotype) were
identified by the presence of a single 321 bp PCR prod-
uct. The homozygous for A allele (AA genotype) were
identified by the presence of both 214 bp and 107 bp
PCR product. The heterozygous individuals (CA geno-
type) were identified by the presence of 321 bp, 214 bp
and 107 bp PCR products. For AGT (M235T) the
homozygous individuals for the M allele (MM genotype)
were identified by the presence of a single 165 bp PCR
product. The homozygous for TT allele (TT genotype)
were identified by the presence of both 140 bp and
25 bp PCR product. The heterozygous individuals (MT
genotype) were identified by the presence of 165 bp,
140 bp and 25 bp PCR products.
Statistical analysis
The measurement data were summarized by the mean ±
standard deviation (SD) and compared with a two-sample
t-test. The enumeration count data were summarized as
the number (%) and compared with a chi-square test (χ2
test). Two analyses were used to evaluate the allelic and
genotypic frequencies that were calculated from the
observed genotypic counts and to assess the Hardy-
Weinberg equilibrium expectations. The same method-
ology was applied to the comparisons between the allelic
and genotypic frequencies. Associations were determined
as odds ratios (ORs) and 95% confidence intervals (CIs).
The odds of carrying a specific allele are defined as the
frequency of subjects in whom the allele occurs divided bythe frequency of subjects in whom the allele does not
occur. An odds ratio for the ACE I/D genotype distribu-
tion χ2 analysis was performed. CAD is the odds of allelic
carriage in the diseased [CAD] group divided by the odds
in the healthy [control] group. The statistical analysis was
performed with the Statistical Package for Social Sciences
for Windows, version 20.0 (SPSS, Inc, Chicago, IL, USA).
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